Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Publication Year:
      2009
    • Abstract:
      Background: The development of novel chemotherapeutic agents in colorectal cancer has improved survival. Following initial response to chemotherapeutic strategies many patients develop refractory disease. This poses a significant challenge common to many cancer subtypes. Newer agents such as Bevacizumab have successfully targeted the tyrosine kinase receptor epidermal growth factor receptor in metastatic colorectal cancer. Human epidermal growth factor receptor-2 is another member of the tyrosine kinase receptor family which has been successfully targeted in breast cancer. This may play a role in colorectal cancer. We conducted a clinicopathological study to determine if overexpression of human epidermal growth factor receptor-2 is a predictor of outcome in a cohort of patients with colorectal cancer. Methods: Clinicopathological data and paraffin-embedded specimens were collected on 132 consecutive patients who underwent colorectal resections over a 24-month period at Mayo General Hospital. Twenty-six contained non-malignant disease. Her-2/neu protein overexpression was detected using immunohistochemistry (IHC). The HER-2 4B5 Ventana monoclonal antibody was used. Fluorescent insitu hybridisation (FISH) was performed using INFORM HER-2/Neu Plus. Results were correlated with established clinical and pathological predictors of outcome including TNM stage. Statistical analysis was performed using SPSS version 11.5. Results: 114 were HER-2/Neu negative using IHC, 7 showed barely perceptible positivity (1+), 9 showed moderate staining (2+) and 2 were strongly positive (3+). There was no correlation with gender, age, grade, Dukes' stage, TNM stage, time to recurrence and 5-year survival (p > 0.05). FISH was applied to all 2+ and 3+ cases as well as some negative cases selected at random. Three were amplified (2 were 3+ and 1 was 2+). Similarly, HER-2 gene overexpression did not correlate with established prognostic indicators. Conclusion: HER-2 protein is over expressed in 11% of colorectal cancer patients. The gene encoding HER-2 is amplified in 3% of cases. Overexpression of HER-2 is not a predictor of outcome. However, patients who over express HER-2 may respond to Herceptin therapy. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of BMC Cancer is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • ISSN:
      14712407
    • Accession Number:
      42408213
  • Citations
    • ABNT:
      KAVANAGH, D. O. et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer, [s. l.], v. 9, p. 1, 2009. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=42408213&custid=s6224580. Acesso em: 27 fev. 2020.
    • AMA:
      Kavanagh DO, Chambers G, O’ Grady L, et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer. 2009;9:1. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=42408213&custid=s6224580. Accessed February 27, 2020.
    • APA:
      Kavanagh, D. O., Chambers, G., O’ Grady, L., Barry, K. M., Waldron, R. P., Bennani, F., Eustace, P. W., & Tobbia, I. (2009). Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer, 9, 1.
    • Chicago/Turabian: Author-Date:
      Kavanagh, Dara O., Gillian Chambers, Liam O’ Grady, Kevin M. Barry, Ronan P. Waldron, Fadel Bennani, Paul W. Eustace, and Iqdam Tobbia. 2009. “Is Overexpression of HER-2 a Predictor of Prognosis in Colorectal Cancer?” BMC Cancer 9 (January): 1. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=42408213&custid=s6224580.
    • Harvard:
      Kavanagh, D. O. et al. (2009) ‘Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?’, BMC Cancer, 9, p. 1. Available at: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=42408213&custid=s6224580 (Accessed: 27 February 2020).
    • Harvard: Australian:
      Kavanagh, DO, Chambers, G, O’ Grady, L, Barry, KM, Waldron, RP, Bennani, F, Eustace, PW & Tobbia, I 2009, ‘Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?’, BMC Cancer, vol. 9, p. 1, viewed 27 February 2020, .
    • MLA:
      Kavanagh, Dara O., et al. “Is Overexpression of HER-2 a Predictor of Prognosis in Colorectal Cancer?” BMC Cancer, vol. 9, Jan. 2009, p. 1. EBSCOhost, search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=42408213&custid=s6224580.
    • Chicago/Turabian: Humanities:
      Kavanagh, Dara O., Gillian Chambers, Liam O’ Grady, Kevin M. Barry, Ronan P. Waldron, Fadel Bennani, Paul W. Eustace, and Iqdam Tobbia. “Is Overexpression of HER-2 a Predictor of Prognosis in Colorectal Cancer?” BMC Cancer 9 (January 2009): 1. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=42408213&custid=s6224580.
    • Vancouver/ICMJE:
      Kavanagh DO, Chambers G, O’ Grady L, Barry KM, Waldron RP, Bennani F, et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer [Internet]. 2009 Jan [cited 2020 Feb 27];9:1. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=42408213&custid=s6224580